RS-SNP: a random-set method for genome-wide association studies by D'Addabbo, Annarita et al.
SOFTWARE Open Access
RS-SNP: a random-set method for genome-wide
association studies
Annarita D’Addabbo
1, Orazio Palmieri
2, Anna Latiano
2, Vito Annese
2, Sayan Mukherjee
3 and Nicola Ancona
1*
Abstract
Background: The typical objective of Genome-wide association (GWA) studies is to identify single-nucleotide
polymorphisms (SNPs) and corresponding genes with the strongest evidence of association (the ‘most-significant
SNPs/genes’ approach). Borrowing ideas from micro-array data analysis, we propose a new method, named RS-SNP,
for detecting sets of genes enriched in SNPs moderately associated to the phenotype. RS-SNP assesses whether
the number of significant SNPs, with p-value P ≤ a, belonging to a given SNP set S is statistically significant. The
rationale of proposed method is that two kinds of null hypotheses are taken into account simultaneously. In the
first null model the genotype and the phenotype are assumed to be independent random variables and the null
distribution is the probability of the number of significant SNPs in S greater than observed by chance. The second
null model assumes the number of significant SNPs in S depends on the size of S and not on the identity of the
SNPs in S. Statistical significance is assessed using non-parametric permutation tests.
Results: We applied RS-SNP to the Crohn’s disease (CD) data set collected by the Wellcome Trust Case Control
Consortium (WTCCC) and compared the results with GENGEN, an approach recently proposed in literature. The
enrichment analysis using RS-SNP and the set of pathways contained in the MSigDB C2 CP pathway collection
highlighted 86 pathways rich in SNPs weakly associated to CD. Of these, 47 were also indicated to be significant
by GENGEN. Similar results were obtained using the MSigDB C5 pathway collection. Many of the pathways found
to be enriched by RS-SNP have a well-known connection to CD and often with inflammatory diseases.
Conclusions: The proposed method is a valuable alternative to other techniques for enrichment analysis of SNP
sets. It is well founded from a theoretical and statistical perspective. Moreover, the experimental comparison with
GENGEN highlights that it is more robust with respect to false positive findings.
Background
The objective of genome-wide association studies
(GWAS) is to identify genetic variants, a subset of single
nucleotide polymorphisms (SNPs), associated with the
onset and progression of complex disease phenotypes at
ag e n o m e - w i d es c a l e[ 1 ] .A l t h o u g hG W A Sh a v ei d e n t i -
fied numerous loci with strong association with com-
mon polygenic diseases [2], these studies have some
limitations. The main source of these limitations is that
SNPs are analyzed independently, requiring large sample
sizes and strong associations to detect an effect. It is
also very difficult using this approach to identify and
incorporate weakly associated SNPs into the analysis.
For polygenic diseases focusing the analysis on only the
most significant SNPs is particularly problematic as no
particular gene may have a large effect [1] but genic
regions weakly associated to the phenotype are impor-
tant when susceptibility is conferred by a large number
of loci, each with a small effect on risk for the disease.
Recently a new trend is emerging in genetics and com-
putational biology in which groups of genes are analyzed
simultaneously for association with a phenotype or disease
[3-5]. The gene sets can be derived from different sources,
for example the sets of genes representing biological path-
ways or sets of genes proximal to each other. By borrow-
ing strength across the gene set, there is potential for
increased statistical power. In addition, in comparing
study results on the same disease from different labs, gene
set approaches may be more reproducible than from indi-
vidual gene studies [6]. In the analysis of gene expression
* Correspondence: ancona@ba.issia.cnr.it
1Istituto di Studi sui Sistemi Intelligenti per l’Automazione - CNR, Via
Amendola 122/D-I, 70126 Bari, Italy
Full list of author information is available at the end of the article
D’Addabbo et al. BMC Genomics 2011, 12:166
http://www.biomedcentral.com/1471-2164/12/166
© 2011 D’Addabbo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.data, this approach is effective at targeting groups of genes
whose constituents show subtle but coordinated expres-
sion changes, this may not be detected by individual gene
analysis. The approach has been quite successful in deriv-
ing new information from expression data [7], and tools
developed for gene set enrichment analysis of gene expres-
sion data abound [8].
The same principle has been recently applied in GWAS
for assessing association of sets of SNPs and phenotypes
[9-12], and many of the proposed approaches can be con-
sidered as extensions to SNP analysis of a method, Gene
Set Enrichment Analysis (GSEA) [3], designed for micro-
array data analysis. Examples are the methods proposed
by Wang et al. [13] and Holden et al. [14]. The basic idea
for both these methodologies is to assign for each gene a
correlation statistic of the gene with the phenotype ana-
logous to the correlation of the phenotype with expres-
sion level of a gene in GSEA. The method proposed by
Wang et al. [13] considers a correlation score based on
the most significant SNP of all the SNPs mapped to a
given gene and uses a Kolmogorov-Smirnov like statistics
for assessing enrichment. The approach implemented by
Holden et al. [14] computes the correlation statistic
based on the association of all the SNPs mapped to a
gene and evaluates the enrichment score of a gene set by
comparing the SNPs in the gene set with the list of the
most associated SNPs in the data set.
In this paper we describe a new methodology that
assesses the association of gene sets to a trait by including
simultaneously strong association signals as well as SNPs
moderately associated to the phenotype. The approach
belongs to the general class of Random Set methods [6,15]
designed to assess enrichment of gene sets in microarray
gene expression data analysis. Our method, named RS-
SNP, assesses whether the number of significant SNPs (p-
value P ≤ a,) belonging to a given gene (SNP) set is statis-
tically significant. The null model we specify assumes that
the genotype and the phenotype are independent and the
number of significant SNPs does not depend on the iden-
tity of the SNP set, but only on the size of the gene (SNP)
set. We use non-parametric permutation procedures [16]
to test against the null. This preserves the linkage disequi-
librium (LD) structure for SNPs in a given chromosomal
region. The performance of RS-SNP on the Crohn’sd i s -
ease (CD) data set collected by the Wellcome Trust Case
Control Consortium (WTCCC) [2] has been evaluated
and compared to the method proposed by Wang et al.
[13], indicated as GENGEN.
Implementation
Defining a SNP set
Before introducing a detailed description of the method
used to perform SNP set analysis, it is important to clar-
ify how a SNP set can be defined.
The first step in defining a SNP set is mapping SNPs
to genes. SNPs may fall within coding regions of genes,
non-coding regions of genes, or in the inter-genic
regions between genes. Each SNP Vi in a GWA study,
with i = 1,..., n, is associated to a gene Gj,w h e r ej
indexes the total M genes, if the gene contains the SNP
o ri st h ec l o s e s tg e n et ot h eS N P .I nc a s e sw h e r eaS N P
is located within shared regions of two overlapping
genes, it is mapped into both genes. SNPs that are a
fixed number of kilo-bases (kb) away from any gene are
not considered. In [13] SNPs are associated to a given
gene if they are within 500 kb. The selection of 500 kb
is due to most enhancers and repressors being <500 kb
away from genes and most LD blocks being <500 kb.
The second step is mapping genes to pathways. The
pathways are pre-defined lists of genes based on a a
priori biological knowledge, for example genes which
are co-expressed in a particular cellular mechanism or
function [17-19]. We use the Molecular Signatures
Database (MSigDB) [3] as a source of gene pathways.
Random set methods
Random Set (RS) scoring methods were primary intro-
duced by Efron and Tibshirani [6] to study the enrich-
ment signal in gene sets analysis by using gene
expression data. The methods they proposed are more
widely applicable.
The main idea pointed out by RS methods is that any
method for assessing gene sets should compare a given
gene set score not only to scores from permutations of
the sample labels, but also taking into account scores
from sets formed by random selections of genes.
In fact, any approach to gene set analysis begins with
the computation of some enrichment score ES(S),f o r
each gene set S, and computes its significance by com-
parison with permutation values ES(S,π).E f r o na n d
Tibshirani in [6] argue that a second kind of comparison
operation, called “row randomization”, is also needed to
avoid bias in the determination of significance.
In order to better clarify RS positions let us consider a
simplified statement of the gene set problem, proposed
by Efron and Tibshirani but adapted to the SNP data
framework.
Let X indicate an n × ℓ matrix of genotypic observa-
tions, where n is the total number of SNPs and ℓ is the
total number of samples, with the first ℓ1 columns of X
representing healthy control samples and the remaining
ℓ2 are case samples, ℓ1 + ℓ2 = ℓ. A statistic Di, i = 1,..., n
is computed for each marker. Consider a single gene set
S with m genes and the hypothesis that S is enriched.
T e s t i n gt h i sh y p o t h e s i si se q u i v a l e n tt oa s k i n gi ft h em
D-values have large magnitude (positive or negative),
w i t hl a r g et ob ed e f i n e d .T h eb a s i ci d e au n d e r l y i n g
enrichment, as nicely stated by Subramanian [3], is that
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the general effect of its D constituent values whether or
not the individual genes are significantly non-zero. Let
DS indicate the set of m D-values in S and
(ES = ES(DS) defines an enrichment test statistic, with
larger value of ES indicating greater enrichment. Testing
S for enrichment requires a distribution under the null
hypothesis for ES. The following are two quite different
models for what the null hypothesis might mean:
￿ Permutation Model.L e tXS be the m × ℓ subma-
trix of X corresponding to S. The null hypothesis
H
perm
0 is that the ℓ columns of XS are independent
and identically distributed m-vectors (i.i.d.). The null
density of ES, gperm(S), is obtained by column
permutations.
￿ Randomization Model. The null hypothesis Hrand
0
is that S has been chosen by random selection of m
SNPs from the full set of n SNPs. In this case the
null density of ES, say grand(S), can be obtained by
row randomization: sets S† of m rows of the data
matrix X are drawn at random, giving randomized
values ES† = ES(DS†). These randomized values are
computed and used to construct an empirical esti-
mate of grand(S).
The randomization of the markers and the permuta-
tion of the labels can be combined into a method that is
called “Restandardization”. Restandardization can be
thought as a method for correcting the permutation
values of ES to take into account the overall null distri-
bution of ES in the randomization model. The restan-
dardized enrichment score (RES) used is defined as:
RES(S) = μ† +
σ†
σ∗(ES(S) − μ∗) (1)
where (μ
†, s
†) are the mean and standard deviation of
ES
† and (μ*, s*) are the corresponding quantities based
on label permutations. Two nested permutation proce-
dures are needed in this case which is computationally
intensive. Fortunately, the RS method has an appealing
feature: for certain choices of the summary statistic
ES = ES(DS) the restandardized score can be easily
computed by analytically calculating the gene-wise
means and standard deviations, without having to draw
random set of genes. As a result evaluation of statistical
significance requires only label permutations [6,15].
Random Set method for SNP data: RS-SNP
RS-SNP is designed for genome-wide SNP data with
binary categorical phenotypes, for example cases and
healthy controls.
The first step in the method is computing a correla-
tion or association statistic Di for each SNP Vi, i = 1,....,
n. The association of a SNP with a trait can be assessed
by considering five different genetic models [20]: gen-
eral, dominant, recessive, multiplicative risk and additive
risk model. The first three models use a c
2 test (or Fish-
er’s exact test) on genotype entries to compute associa-
tion. The multiplicative risk model uses a c
2 test or
Fisher’s exact test on allelic entries to compute associa-
tion. The additive risk model uses a Cochran-Armitage
test for trend [21] to associate a SNP to disease risk of
association.
After computing the single SNP associations, RS-SNP
computes the enrichment of these associations in a pre-
defined gene set S. The mapping of each SNP Vi to
genes is discussed above. The relevant components of
the method include:
￿ n = the number of genotyped SNPs;
￿ d = the number of SNPs with p-value P less than
or equal to a given threshold a;
￿ m = the number of SNPs in S;
￿ y = the number of SNPs belonging to S with p-value
P ≤ a.
RS-SNP assesses whether the number y of SNPs asso-
ciated to the phenotype and belonging to S is compati-
ble with chance or indicates over-representation of
associated SNPs in gene set S. Assessing the statistical
significance of y requires the distribution of y under two
null hypotheses, as previously stated [6]. The first null
hypothesis considered is the hypothesis in which there
is no association between genotype and phenotype
(H
perm
0 ). In particular, the method assesses the probabil-
ity of observing values of y greater than the observed
ones when genotype and phenotype are independent
random variables. In addition, a second cause of ran-
domness for y comes from S. Knowing that d of n SNPs
have p-value P ≤ a and that y of them fall in a gene set
S with size m, how many SNPs fall in a set composed
of m SNPs drawn randomly from the n SNPs available?
To take into account this source of randomness, the
probability of observing values of y greater than the
ones observed in the actual experimental conditions has
to be assessed under the hypothesis (Hrand
0 ) that the m
loci in the gene set S have been chosen randomly from
the full set of n SNPs. Note that this problem is easy to
solve since under this model the distribution for y is
hypergeometric Hyp(m, d, n) with mean μ =
dm
n
and
variance σ2 =
dm
n

1 −
d
n

n − m
n − 1
. To assess the statis-
tical significance of y under the two null hypotheses
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(1) Permute the labels of the samples Π times. For
each permutation π = 1, ..., Π:
(i) Compute the number of significant SNPs
d∗
π = # {i = 1,....,n : p ≤ α}.
(ii) Compute the number of significant SNPs
belonging to S, y∗
π.
(iii) Compute the mean μ∗
π and variance σ∗2
π
under the hypergeometric distribution
Hyp(m,d∗
π,n).
(iv) From the above y∗
π, μ∗
π,a n dσ∗2
π compute
RES(S,π).
(2) Compute the p-value
H
perm
0 : P =
1
 
  
π=1
I{RES(S,π) ≥ RES(S)},
where I is the indicator function.
Since several gene sets are considered in the analysis,
the false-discovery rate (FDR) and the family-wise error
rate (FWER) are computed as proposed by Wang et al.
[13] in order to control multiple hypothesis testing.
FDR, i.e. the fraction of expected false-positive find-
ings, is calculated as:
FDR(RES(S)) =
1
 
 
π=1
T
t=1 I{RES(St,π) ≥ RES(S)}
T
t=1 I{RES(St) ≥ RES(S)}
,
where T is the total number of gene sets. The FWER
is evaluated as the fraction of all permutations whose
highest standardized enrichment score in all gene sets is
higher than the RES(S) for a given gene set:
FWER(RES(S)) =
1
 
  
π=1
I

T 
t=1
I{RES(St,π) ≥ RES(S)}

.
Results and Discussion
Experimental data set
WTCCC data set
The data set provided by WTCCC is composed of 2005
Crohn’s Disease (CD) patients and 3004 healthy controls
(HC). The control individuals came from two sources:
1504 individuals from the 1958 British Birth Cohort (58
C) and 1500 individuals selected from blood donors
recruited as part of the WTCCC project (UK Blood Ser-
vices (UKBS) controls). All 5009 samples were geno-
typed with the GeneChip 500 K Mapping Array set
(Affymetrix chip), which comprises 500,568 SNPs. The
quality control analysis was carried out following the
details specified by WTCCC [2]. In particular, 257 CD
and 66 HC subjects were excluded from the study, redu-
cing the number of CD to 1748 and the number of HC
to 2938 subjects. Moreover, markers were excluded with
the following criteria:
￿ SNPs with Hardy-Weinberg exact p-value P <5 . 7
×1 0
-7 in the combined set of 2938 controls;
￿ SNPs with p-value P <5 . 7×1 0
-7 f o re i t h e rao n e
or two-degree of freedom test of association between
the two control groups;
￿ SNPs with a MAF < 1%.
In total, n = 414, 483 SNPs in autosomal chromo-
somes passed the quality control filters. More detailed
information on WTCCC data set are in [2].
SNP set construction
Two different collections of gene sets were used, that
can be downloaded from the MSigDB website http://
www.broad.mit.edu/gsea/msigdb/index.jsp:
￿ MSigDB C2 CP collection, composed of pathways
collected from various sources such as online data-
bases, biomedical literature in PubMed, and knowl-
edge of domain experts. In particular, the canonical
pathways (CP) collection consists of 639 gene sets;
￿ MSigDB C5 collection, composed of 1454 gene sets
derived from Gene Ontology (GO). This collection is
composed of 825 GO biological processes, 233 GO
cellular components and 396 GO molecular functions.
We have considered only those GO terms associated
with a specific reference that describes the work or
analysis upon which the association between a specific
GO term and gene product is based. Each annotation
includes an evidence code to indicate how the annota-
tion to a particular term is supported http://www.gen-
eontology.org/GO.evidence.shtml. Only associations
with the following evidence codes are included in
MSigDB gene sets: IDA IPI, IMP IGI, IEP ISS, TAS.
Moreover, GO gene sets for very broad categories,
such as Biological Process, have been omitted from
MSigDB. GO gene sets with fewer than 10 genes have
also been omitted. Gene sets with the same members
have been resolved based on the GO tree structure: if
a parent term has only one child term and their gene
sets have the same members, the child gene set is
omitted; if the gene sets of sibling terms have the same
members, the sibling gene sets are omitted.
The mapping of SNPs to genes has been carried out
by using the Affymetrix annotation files Mapping250 K
Nsp Annotations and Mapping250 K Sty Annotations,
CSV format, version 26. In this study, SNPs were
assigned to a given gene if they are within 5 kb from it.
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Results on MSigDB C2 CP collection
The association of each SNP to CD was assessed by
using the Cochran-Armitage trend test with 1 degree of
freedom [21]. A significance threshold a =0 . 0 1w a s
used and d = 6803 signals with p-value P ≤ a were
found.
Statistical significance and adjustment for multiple
hypothesis testing were determined by a permutation-
based procedure with Π = 10,000 random permutations
of the phenotypic status of the subjects. The FDR and
FWER were also computed.
The enrichment analysis highlighted 86 pathways (p-
value P ≤ 0.05) enriched in SNPs weakly associated to
the trait. The enrichment analysis, performed by GEN-
GEN on C2 CP collection, highlighted 115 pathways (p-
value P ≤ 0.05) enriched in SNPs weakly associated to
the trait. Intersecting the two lists of gene sets found to
be significant by RS-SNP and GENGEN resulted in 47
pathways.
Detailed tables, concerning the list of significant path-
ways in MSigDB C2 collection obtained by RS-SNP and
GENGEN methods, are reported in the additional file 1.
Results on MSigDB C5 collection
The association of each SNP to CD was computed using
the same methodology as above. Statistical significance
and adjustment for multiple hypothesis testing was also
estimated using the same procedure as stated above
with Π = 10,000 random permutations of the phenoty-
pic status of the subjects.
The enrichment analysis performed by RS-SNP on the
MSigDB C5 collection highlighted 196 pathways (p-
value P ≤ 0.05) enriched in SNPs weakly associated to
the trait. The enrichment analysis performed by GEN-
GEN on MSigDB C5 collection highlighted 256 path-
ways (p-value P ≤ 0.05) enriched in SNPs weakly
associated to the trait. Intersecting the lists of gene sets
resulted in 89 pathways.
Detailed tables, concerning the list of significant path-
ways in MSigDB C5 collection obtained by RS-SNP and
GENGEN methods, are reported in the additional file 2.
Computational complexity evaluation
To evaluate and compare the computational cost of RS-
SNP and GENGEN we used a computer equipped with
two quadcore 2.67 GHz processors, 24 Gbyte of RAM,
working under Linux OS. The first step, common to
both the algorithms, was to assess the association
between each SNP and the phenotype. The computation
of the additive trend test statistics on the whole set of
markers available in the WTCCC data required 18 sec
for the actual phenotypic status of the samples and 50
min for random permutations of their phenotypic status.
The second step was to assess the statistical significance
of the enrichment score, under both the null and
alternative hypotheses, for each of the 639 gene sets of
the considered C2 CP collection. This step required 29
min for RS-SNP and 50 min for GENGEN. These com-
putational costs indicate that the algorithmic complexity
of both approaches is comparable.
Discussion
We conclude with a discussion of the biological and sta-
tistical aspects of the RS-SNP approach. The FDR seems
the most relevant summary statistic in this type of ana-
lysis as the number of true positives is expected to be a
small fraction of the total number of hypotheses tested.
More sophisticated scores can be used to measure
enrichment instead of the simple indicator function.
However, an advantage of the scoring we propose is
that it assigns equal weights both to markers strongly
associated to CD as well as markers with moderate asso-
ciation, markers with with p-value P =1×1 0
-10 and P =
1×1 0
-3 are treated equally. This property of the score
ensures that the enrichment of a gene set is due to the
simultaneous presence of many markers with association
and not a few with strong association. The methodology
also corrects for gene set size automatically.
The linkage disequilibrium (LD) structure is preserved
by the proposed method and does not alter the statisti-
cal significance of the identified pathways. This is due to
the fact that the method uses random permutations of
the phenotypic status of the subjects in the sample to
assess the significance of the enrichment score. The col-
umn permutation procedure does not modify the geno-
typic profile of the subjects because it limits itself to
assign randomly phenotypic states to subjects. The row
permutation procedure adopted by the method has the
objective of normalizing the enrichment score. This is
realized comparing the actual number of markers asso-
ciated to the phenotype in the gene set with the one
obtained by chance. So, the LD structure of a given
gene set remains the same under both null and alterna-
tive hypothesis. Finally note that the row permutations
are only implicitly realized in our approach. This is due
to the fact that the number of markers belonging to the
gene set and associated to the trait has a hypergeometric
distribution. For this reason the computational complex-
ity of RS-SNP is proportional only to the number of col-
umn permutations required, that is equal to the inverse
of the minimum observable P-value.
From a biological point of view, significant associations
were highlighted by RS-SNP analysis between CD and key
inflammatory pathways. Some of the highlighted pathways
were also found to be associated to CD and other inflam-
matory diseases (rheumatoid arthritis and type I diabetes)
by another pathway based method [22]: HSA04630 JAK
STAT SIGNALING PATHWAY, HSA04612 ANTIGEN
PROCESSING AND PRESENTATION, HSA04514 CELL
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KILLER CELL MEDIATED CYTOTOXICITY and
HSA04640 HEMATOPOIETIC CELL LINEAGE. Other
pathways such as L6, HSA04940 TYPE I DIABETES MEL-
LITUS, ERK, and IL10 have been associated in the litera-
ture to CD [22]. We also found pathway hits for calcium
signaling, CREB pathway, IL2 and IL12 which were also
found in Torkamani [23] and Wang et al. [9]. These find-
ings are consistent with known functional roles of these
pathways in intestinal immune response to microbial
infection and injury, signal transduction in response to a
variety of extracellular signals including neurotransmitters,
hormones, membrane depolarization, and growth, and
neurotrophic factors and the exaggerated response
observed in CD.
A comparative study of RS-SNP and GENGEN suggests
that gene set methods that use both types of null hypoth-
eses may reduce false positives, GENGEN does not rando-
mize with respect to gene set size. It is worth noting that
GENGEN found a greater number of significant pathways,
but several pathways of these pathways may be false posi-
tives. For example, the HSA04810 REGULATION OF
ACTIN CYTOSKELETON pathway was found significant
by GENGEN. This is a very large pathway composed of
166 genes and 2650 SNPs. Only 32 SNPs are weakly asso-
ciated (p-value P ≤ 0.01) to CD and RS-SNP assigned a
p-value P =0 . 8 2t ot h i sp a t h w a y .T h i st y p eo fr e s u l ti s
recapitulated with several pathways in the analysis.
Conclusions
A new method for detecting association of SNP sets to a
trait has been proposed. The approach, named RS-SNP,
assesses whether the number of SNPs associated to the
phenotype and belonging to a given SNP set is statisti-
cally significant. Strong signals as well as SNPs weakly
associated to the trait are taken into account simulta-
neously for assessing association of a given SNP set. The
proposed method, well founded from a theoretical per-
spective, is a valuable alternative to other techniques for
enrichment analysis of SNP sets. When applied to the
CD data set collected by the WTCCC, the method high-
lighted many relevant pathways which play a key role in
CD as well as in other inflammatory diseases.
Availability and requirements
The RS-SNP approach has been implemented in Matlab
in the compute_rs.m file (see additional file 3). More-
over, a combine_rs.m program can be used that allows
to combine results obtained by running several times
compute_rs.m on the same data, splitting the time-
consuming permutation procedure in several blocks.
The combine_rs.m program generates a single test
statistics for all candidate pathways.
To compute the association of each single SNP with
the trait, the compute_association.m program is also
enclosed in the RS-SNP package. It allows to perform
sample and marker quality controls and then to test the
association by choosing the more suitable genetic model.
Additional material
Additional file 1: Experimental results of RS-SNP and GENGEN on
MSigDB C2 collection. Tables reporting the experimental results
obtained by the proposed method, RS-SNP, and by GENGEN on the
MSigDB C2 pathway collection.
Additional file 2: Experimental results of RS-SNP and GENGEN on
MSigDB C5 collection. Tables reporting the experimental results
obtained by the proposed method, RS-SNP, and by GENGEN on the
MSigDB C5 pathway collection.
Additional file 3: RS-SNP package. The proposed RS-SNP software is
contained in this compressed file, together with: ￿ the help
documentation, ￿ example files with the SNP-gene mapping and gene-
pathway mapping; ￿ example of input files.
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